西藏加快推进医药产业高质量发展

Core Insights - The Tibet Autonomous Region is focusing on high-quality development of the pharmaceutical industry and drug safety by 2025, with ongoing revisions to the "95 National Standard for Tibetan Medicine" and submission of quality standard drafts for various products [1][2] Group 1: Industry Development - The Tibet Drug Administration has processed 9,511 approval items and issued over 2,700 electronic certificates, achieving a 100% completion rate for online administrative licensing [2] - There are currently 13 new drug varieties under research in the region, indicating a strong development momentum in Tibetan medicine [2] - The production value of Tibetan medical devices has reached over 10 million yuan, contributing to the innovation and development of Tibetan medicine [2] Group 2: Regulatory and Supportive Measures - The establishment of a one-on-one service guidance system aims to reduce risks and uncertainties for enterprises during market entry [2] - New policies have been introduced to support investment and promote high-quality development in the pharmaceutical industry, including the acceptance of incomplete application materials [2] - The approval of three Class 1 innovative drugs from Haikang Pharmaceutical Group marks a significant breakthrough for innovative drugs in Tibet [2] Group 3: Growth Metrics - Compared to 2020, Tibet has seen an increase of 35 new drug production enterprises and 18 wholesale enterprises, along with 44 new drug varieties and 50 approved numbers [3] - The production value of pharmaceuticals in 2024 is projected to increase by 3 billion yuan compared to 2020, with Tibetan medicine production valued at 3.4 billion yuan [3]